Pricing Log in Create free account
Saturday 17 October 2026 Export MYO’s income statement to Excel — free account

Myomo, Inc.

MYO Healthcare Medical Devices

Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024. In the quarter to June 2026, revenue grew 21.3%, EPS grew 18.2%, free cash flow grew 80.0% and total debt rose 199.5%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

1.20 0.10 −7.69%
Market cap
$51.5M
P/E
0.0×
Fwd P/E
−4.2×
Dividend yield
—
F-score
2/9
Altman Z
−3.04
Beneish M
−2.81
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.44
Total sells 0.21
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 2 — — — 3 — 3 1 — — — —
Sell — — — — — — 2 — — 2 2 —
Insider Ownership 15.85%

Capital & Financial Ratios $m

Market Cap 51.49
Revenue 43.26
Net Income (14.51)
Free Cash Flow (9.09)
Net Debt (1.47)
Current Ratio 2.31 (at or above 1.5: strong)
Debt/Equity 2.06 (above 2: weak)
P/E ratio 0.00
Fwd P/E (4.24) (negative: loss-making)
P/S ratio 1.18
P/B ratio 8.79 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 15.14% (at or above 15%: strong)
Next Y EPS Growth 24.20% (at or above 15%: strong)
Next Y revenue growth 11.42% (at or above 10%: strong)
Next 5Y EPS Growth 21.35% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 2.3×; over the ten years it ranged from −1.3× in 2020 to 20.7× in 2018.
P/S against its own 10 years 24.56%
10-year low 10-year high
P/B against its own 10 years 82.33%
10-year low 10-year high
EV/Sales against its own 10 years 31.35%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9 25 18 13
Receivables 2 4 4 5
Inventory 2 3 3 3
Other — — — —
14 33 28 25
2023 2024 2025 Q'26
Payables 5 9 6 8
ST’ Debt — — — 0
Other — — 1 1
5 10 8 11

Compound Annual Growth %

10y 5y 3y
Sales 50.43% 40.10% 38.05%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (0.28%) 21.49%

Revenue $m

Mar Jun Sep Dec Year
’26 10 12 — — —
’25 10 10 10 11 41
’24 4 8 9 12 33
’23 3 6 5 5 19
’22 4 4 4 4 16
’21 2 3 4 4 14
’20 1 1 2 4 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (3) (9) (2) (1) (15)
’24 (3) (2) (1) 3 (3)
’23 (2) 0 (2) (2) (6)
’22 (2) (3) (3) (2) (10)
’21 (2) (3) (2) (2) (10)
’20 (2) (4) (2) (1) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (2) — — —
’25 (3) (10) (3) (1) (18)
’24 (3) (2) (2) 3 (5)
’23 (2) 0 (2) (2) (6)
’22 (2) (3) (3) (2) (10)
’21 (2) (4) (2) (2) (10)
’20 (2) (4) (2) (1) (9)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.07) (0.09) — — —
’25 (0.08) (0.11) (0.09) (0.09) (0.37)
’24 (0.10) (0.03) (0.03) (0.01) (0.16)
’23 (0.11) (0.04) (0.06) (0.07) (0.28)
’22 (0.41) (0.42) (0.40) (0.29) (1.52)
’21 (0.57) (0.46) (0.36) (0.52) (1.89)
’20 (2.51) (1.12) (0.70) (0.37) (3.67)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — 62.10 41.70 7.80 2.82 6.50 0.37 0.37 2.51 0.71

Analyst estimates 2026–2028

Powerpack
High — 695.88 168.90 54.00 40.00 18.88 8.79 5.58 6.75 7.17
People
People Employees 23 24 46 50 64 93 106 106 185 195
Revenue/emp, $m 0.05 0.06 0.05 0.08 0.12 0.15 0.15 0.18 0.18 0.21
Income, $m
Income, $m Revenue 1 2 2 4 8 14 16 19 33 41
Gross margin, % 74.42 67.59 70.20 62.98 65.71 74.42 65.91 68.51 71.23 65.70
EBT (4) (12) (10) (11) (12) (10) (11) (8) (6) (15)
EBT margin, % (327.83) (776.03) (422.11) (279.15) (152.49) (74.21) (68.47) (41.53) (17.87) (36.82)
Net income (4) (12) (10) (11) (12) (10) (11) (8) (6) (16)
Depreciation 0 0 0 0 0 0 1 0 1 2
Per share, $
Per share, $ Revenue 31.26 10.84 5.96 6.93 2.28 2.38 2.21 0.65 0.86 0.98
Earnings (102.37) (87.99) (25.22) (19.35) (3.67) (1.89) (1.52) (0.28) (0.16) (0.37)
Cash flow (90.73) (42.79) (23.43) (18.67) (2.71) (1.64) (1.45) (0.21) (0.09) (0.35)
Capex (0.05) (0.47) (0.31) (0.09) (0.01) (0.06) (0.02) 0.00 (0.04) (0.08)
Free cash flow (90.78) (43.26) (23.74) (18.76) (2.73) (1.69) (1.47) (0.21) (0.12) (0.43)
Book value (137.63) 86.55 15.67 3.29 3.47 2.64 0.90 0.30 0.65 0.27
Shares, m 0 0 0 1 3 6 7 29 38 42
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 10.10 7.25 1.30 2.96 2.88 0.24 7.34 7.47 0.93
P/B 0.00 1.27 2.76 2.74 1.94 2.59 0.58 15.72 9.84 3.34
EV/Sales 0.00 2.62 5.10 0.83 1.36 1.81 (0.07) 6.92 6.73 0.79
EV/FCF (2.01) (0.66) (1.28) (0.31) (1.14) (2.55) 0.11 (21.07) (47.10) (1.82)
Cash, $m
Cash, $m Operating cash flow (3) (6) (10) (10) (9) (10) (10) (6) (3) (15)
Capex 0 0 0 0 0 0 0 0 (1) (3)
Free cash flow (3) (6) (10) (10) (9) (10) (10) (6) (5) (18)
Balance, $m
Balance, $m Working capital (2) 12 6 2 12 15 6 8 23 19
Total debt 3 — — 3 0 0 0 — — 11
Net debt 3 (13) (7) (2) (12) (15) (5) (9) (25) (7)
Shareholders’ equity (5) 12 6 2 12 15 6 9 25 11
Returns, %
Returns, % ROA (276.84) (161.95) (92.71) (154.71) (114.83) (63.28) (70.87) (65.86) (21.76) (38.51)
ROIC 0.00 0.00 0.00 (55,759.30) 0.00 (2,241.55) (549.61) (4,169.11) 0.00 (212.70)
ROE 27.90 497.94 (109.34) (279.03) (182.74) (81.65) (98.50) (106.17) (36.69) (86.24)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Myomo, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MYO Myomo, Inc. $51.5M — (loss-making) — (loss-making) +21.26% (above 0%: growing) n/m +80.02% (above 0%: growing) 72.13% (19.26%)
COCH Envoy Medical, Inc. $49.9M — (loss-making) — (loss-making) −34.62% (below 0%: shrinking) n/m −22.44% (below 0%: shrinking) (445.10%) (10,919.61%) Compare
MDAI Spectral AI, Inc. $49.6M — (loss-making) — (loss-making) −30.42% (below 0%: shrinking) n/m −21.86% (below 0%: shrinking) 31.58% (122.70%) Compare
TLIS Talis Biomedical Corporation $46.3M — (loss-making) — (loss-making) −94.01% (below 0%: shrinking) n/m +23.80% (above 0%: growing) 91.78% 0.00% Compare
SRTS Sensus Healthcare, Inc. $45.6M — (loss-making) — (loss-making) −68.69% (below 0%: shrinking) n/m −201.65% (below 0%: shrinking) 33.58% (138.86%) Compare
TELA TELA Bio, Inc. $45.6M — (loss-making) — (loss-making) −4.49% (below 0%: shrinking) n/m −17.72% (below 0%: shrinking) 72.77% (48.12%) Compare
SNWV Sanuwave Health Inc. $44.5M 3.0× — (loss-making) −3.13% (below 0%: shrinking) n/m +86.75% (above 0%: growing) 76.23% (2.88%) Compare
XTNT Xtant Medical Holdings, Inc. $42.5M — (loss-making) — (loss-making) −34.96% (below 0%: shrinking) n/m −881.96% (below 0%: shrinking) 57.88% (39.81%) Compare
RPID Rapid Micro Biosystems, Inc. $42.4M — (loss-making) — (loss-making) +10.91% (above 0%: growing) n/m −23.97% (below 0%: shrinking) 15.05% (152.99%) Compare
Median of peers $45.6M — — −32.52% — −22.15% 45.73% (85.41%)

All 149 Medical Devices stocks →

Myomo, Inc. (MYO) key facts

  • Strength: Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024.
  • Myomo, Inc. (MYO) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
  • As of October 16, 2026, MYO traded at $1.20, a market capitalization of $51.5 million.
  • Return on equity was −86.2% and debt-to-equity 2.06.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −3.04 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Myomo, Inc. (MYO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MYO · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com